Media Coverage Year 2023 2022 2021 2020 2019 2018 2017 2016 Search Bloomberg Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program Dec 01 2022 PR Newswire At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma Mar 28 2022 Yahoo Finance Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer Jan 20 2022 PR Newswire Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma Dec 17 2021 Yahoo Finance Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting Dec 16 2021 Time Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference Oct 20 2021 PR Newswire Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations Sep 10 2021 Taiwan News Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed Aug 31 2021 1 2 3 4